NANETS is pleased to offer a Virtual Poster Hall to showcase 100 high quality research posters. Below is the list of poster titles and presenters. Complete abstracts and poster PDFs will be made available when the Virtual Poster Hall opens on October 2, at 9am ET. If this changes, an update will be posted here.

If you are a poster presenter, click here for instructions. 

Navigating the Virtual Poster Hall

The virtual platform, VFairs, offers an interactive experience between attendees and poster presenters. Chat with presenters each morning before the Symposium begins and during extended breaks throughout the day. Review the schedule here and plan your visits to the Virtual Poster Hall! More information will be provided as we get closer to Symposium.

Poster Categories 

Basic Science

Applied Basic Science

Clinical - Chemotherapy, SSA and Biologics

Clinical - PRRT, Nuclear Medicine and Imaging

Clinical - Surgical and Applied Pathology

Population Science

Trials in Progress

Other Science

Posters

Basic Science

B-1 - Oral Abstract Presenter - Metastatic Pancreatic Neuroendocrine Tumors Have Decreased Somatostatin Expression and Increased Akt Signaling, Catherine Tran, MD, University of Iowa, Department of Surgery, Abstract ID: 104

B-2 - Oral Abstract Presenter - Proteotranscriptomic Classification and Characterization of Pancreatic Neuroendocrine Neoplasms, Kevin Yang, BS, BC Cancer, Canada's Michael Smith Genome Sciences Centre, Abstract ID: 105

B-3 - Telotristat Ethyl Augments Cytotoxic Chemotherapy Response in Preclinical Tumor Models, Niranjan Awasthi, PhD, Indiana University School of Medicine - South Bend, Abstract ID: 120

B-4 - Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest, Mark Kidd, Wren Laboratories, Abstract ID: 158

B-5 - Exploring Plasma-Derived Exosomes (PDEs) as a Response Biomarker in Neuroendocrine Tumors (NETs), Medhavi Gupta, MD, Roswell Park Cancer Center, Department of Medicine, Abstract ID: 177

B-6 - The Anti-Proliferative Effects of the Mycotoxin Verrucarin A on Neuroendocrine Tumor Cells, Jason Whitt, PhD, UAB, Department of Surgery, Abstract ID: 182

B-7 - MAML3 Overexpression Increases Tumorgenicity in Several Neuroendocrine Tumor Types, Lauren Fishbein, MD, PhD, University of Colorado School of Medicine, Abstract ID: 187

B-8 - Oral Abstract Presenter - The Lineage Transcription Factors ASCL1, NKX2-1, And PROX1 Form A Regulatory Network And Control the Expression of the Ion Channel, SCN3A, in Small Cell Lung Cancer, Karine Pozo, PhD, UT Southwestern Medical Center, Abstract ID: 195

B-9 - 5-Azacitidine Inhibits Neuroendocrine Tumors via the Induction of Notch3 by the Transactivator BORIS, Rui Zheng-Pywell, MD, University of Alabama Birmingham, Abstract ID: 203

[return to category list

Applied Basic Science

B-10 - The Importance of Dedicated Nurse Navigation for PRRT Therapy, Rebecca Mirro, BSN, RN, UCSF, GI Oncology, Abstract ID: 29

B-11 - Clinicopathological and Genomic Features in Patients With Head and Neck Neuroendocrine Carcinoma, Akihiro Ohmoto, MD, PhD, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Division of Medical Oncology,  Abstract ID: 101

B-12 - Oral Abstract Presenter - Functional Genetic Screen To Identify Drivers Of Pancreatic Neuroendocrine Tumor Pathogenesis, Chandra Kumar Maharjan, BS, The University of Iowa, Neuroscience and Pharmacology, Abstract ID: 132

B-13 - Oral Abstract Presenter - Efficacy Of Combined MEK And CDK Targeted Therapies For Pancreatic Neuroendocrine Tumors, Ume Salma Shaik Amjad, PhD, University of Iowa, Neuroscience and Pharmacology, Abstract ID: 146

B-14 - A Blood-Based Neuroendocrine Tumor Mrna Signature Identifies Residual Tumor And Accurately Predicts Recurrence After Surgery, Irvin Modlin, MD, Yale University School of Medicine, Abstract ID: 148

B-15 - Mapping Anti-Angiogenic Proteome Associated With Black Raspberry Extract And Gallic Acid In Neuroendocrine Cancer, Nicholas Skill, PhD, Indiana University, Surgery, Abstract ID: 179

B-16 - Oral Abstract Presenter - A Systematic Workflow to Identify Anti-cancer Drugs Targeting Small Bowel Neuroendocrine Tumors and Neuroendocrine Carcinomas, Po Hien Ear, PhD, University of Iowa, Department of Surgery, Abstract ID: 196

B-17 - Preclinical Evaluation of Radionuclide Therapy Targeting CXCR4 and Thioredoxin Reductase in Atypical Carcinoid and Neuroendocrine Carcinoma, Dijie Liu, PhD, University of Iowa, Abstract ID: 198

[return to category list

Clinical - Chemotherapy, SSA and Biologics

C-1 - Oral Abstract Presenter - Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors, Bassel El-Rayes, MD, Winship Cancer Institute at Emory University, Hematology and Oncology, Abstract ID: 111

C-2 - Real-World Observational Study of Somatostatin Analogs and Rescue Medication Use for Neuroendocrine Tumors in Canada, Daniel Rayson, MD, Nova Scotia Cancer Center, Dalhousie University, Abstract ID: 112

C-3 - Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome Outcomes: Interim Analyses of the XERMELO Patient Registry, Christina Darden, BS, RTI Health Solutions, Abstract ID: 113

C-4 - Carcinoid Syndrome (CS) Improvements in Patients Receiving Telotristat Ethyl (TE): Findings from TELEPRO-II, Matthew Kulke, MD, Boston University/Boston Medical Center, Abstract ID: 115

C-5 - Efficacy of Telotristat Ethyl (TE) in Patients with Progressive Neuroendocrine Tumor Disease: Real World Clinical Practice Experience, Eric Liu, MD, The Neuroendocrine Institute at Rocky Mountain Cancer Centers, Abstract ID: 117

C-6 - Efficacy Of Checkpoint Inhibitors In Neuroendocrine Neoplasms: The Mayo Clinic Experience, Jennifer Gile, MD, Mayo Clinic College of Medicine, Division of Medical Oncology, Department of Oncology, Abstract ID: 125

C-7 - Safety In Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT), Aman Chauhan, MD, University of Kentucky Markey Cancer Center, Abstract ID: 130

C-8 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study, Marianne Pavel, PhD, Friedrich Alexander University Erlangen-Nürnberg, Department of Medicine, Abstract ID: 135

C-9 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study, Marianne Pavel, PhD, Friedrich Alexander University Erlangen-Nürnberg, Department of Medicine, Abstract ID: 136

C-10 - Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors, Alex Liu, MD, Mayo Clinic, Abstract ID: 143

C-11 - Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience, Amr Mohamed, MD, UH Seidman Cancer Center, Case Western Reserve University, Division of Hematology and Medical Oncology, Abstract ID: 149

C-12 - Oral Abstract Presenter - A Single-Centre Pilot Study for Radiosensitization of Everolimus with External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis, Sten Myrehaug, MD, University of Toronto, Radiation Oncology ,Abstract ID: 152

C-13 - Efficacy Of FOLFOX With Or Without Bevacizumab In Patients With Aggressive Pancreatic NETs After Prior Capecitabine/Temozolomide, Taymeyah Al-Toubah, MPH, H. Lee Moffitt Cancer Center & Research Institute, Gastrointestinal Oncology ,Abstract ID: 156

C-14 - Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms, Taymeyah Al-Toubah, MPH, H. Lee Moffitt Cancer Center & Research Institute, Gastrointestinal Oncology, Abstract ID: 157

C-15 - Concurrent Everolimus with Hepatic Transarterial Bland Embolotherapy (Evero-Embo) in Patients with Metastatic Well Differentiated Neuroendocrine Tumor (NET), Lowell Anthony, MD, University of Kentucky, Internal Medicine/Medical Oncology, Abstract ID: 159

C-16 - Comparative Outcomes Of Second Line Topoisomerase I Inhibitor-Containing Therapies On Extrapulmonary Neuroendocrine Carcinoma, Ho-Man Yeung, MD, Fox Chase Cancer Center ,Abstract ID: 162

C-17 - The Clinical Impact of Serum Chromogranin-A in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS), Amr Mohamed, MD, UH Seidman Cancer Center, Case Western Reserve University, Division of Hematology and Medical Oncology, Abstract ID: 163

C-18 - Avelumab in Unresectable/Metastatic, Progressive, Grade 2-3 Neuroendocrine Neoplasms (NEN): Combined Results from NET-001 and NET-002 Trials, David Chan, MBBS, University of Toronto, Medicine, Abstract ID: 164

C-19 - Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review, Bryan Le, BS, University of California, San Francisco, Gastrointestinal Oncology, Abstract ID: 185

C-20 - Efficacy of Somatostatin Analog (SSA) Monotherapy for Well-Differentiated Grade 3 (G3) gastroenteropancreatic Neuroendocrine Tumors (NETs), Patrick McGarrah, MD, Mayo Clinic, Division of Medical Oncology, Department of Oncology, Abstract ID: 200

[return to category list]   

Clinical - PRRT, Nuclear Medicine and Imaging

C-21 - Efficacy And Safety Of Peptide Receptor Radionuclide Therapy In Lung Neuroendocrine Tumors: A Multicentre Study, Amir Iravani, MD, Peter MacCallum Cancer Centre, Molecular Imaging and Therapeutic Nuclear Medicine, ENETS Centre of Excellence, Abstract ID: 15

C-22 - Patient Travel Concerns After Treatment with Peptide Receptor Radionuclide Therapy (PRRT), Ayse Kendi, MD, Mayo Clinic, Department of Radiology, Abstract ID: 36

C-23 - 177Lu-DOTATATE/DOTATOC Re-Treatment In Patients With Progressive Neuroendocrine Tumours: A Systematic Review And Meta-Analysis, Jonathan Strosberg, MD, Moffitt Cancer Center, Abstract ID: 43

C-24 - A Clinical Score(CS) for Well-Differentiated Neuroendocrine Tumor(WD-NET) Patients(Pts) Undergoing Peptide Receptor Radionuclide Therapy(PRRT), Satya Das, MD, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Abstract ID: 44

C-25 - The Use of Peptide Receptor Radionucleotide Therapy (PRRT) in Patients with Neuroendocrine Tumor Cardiac Metastases, Irene Yu, MD, BC Cancer, Abstract ID: 58

C-26 - Safety of 177Lu‑DOTATATE in Patients with Advanced Neuroendocrine Tumors: Data from a US Expanded Access Program, Edward Wolin, MD, Icahn School of Medicine at Mount Sinai, Center for Carcinoid and Neuroendocrine Tumors at the Tish Cancer Institute, Abstract ID: 118

C-27 - Re-Treatment with 177Lu-DOTATATE in Patients with Neuroendocrine Tumors: Multicenter Real-World Experience, Shaunak Navalkissoor, MD, Royal Free London NHS Foundation Trust, Abstract ID: 119

C-28 - Supportive Management during PRRT for Symptomatic Pheochromocytomas or Paragangliomas, Erica Tsang, MD, University of British Columbia, Medical Oncology, Abstract ID: 134

C-29 - Gallium-68 Dotatate PET/CT (Ga68PET/CT) Versus Contrast Enhanced Cross Sectional Imaging (CECSI) to Measure Treatment Response (TR) to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Neuroendocrine Tumors (NETs), Dane Jackson, MD, Virginia Mason Medical Center, Radiology, Abstract ID: 145

C-30 - 64Cu-DOTATATE PET in Neuroendocrine Tumor Patients: What We Learned From the First 1,200 Patients, Andreas Kjaer, MD, PhD, Rigshospitalet & University of Copenhagen, Clinical Physiology, Nuclear Medicine & PET, Abstract ID: 147

C-31 - PRRT Neuroendocrine Tumor Response Monitored Using Circulating Transcript Analysis: The NETest, Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center, Abstract ID: 160

C-32 - Dynamic Contrast-Enhanced CT to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation, John Hudson, MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Radiation Oncolog, Abstract ID: 165

C-33 - Association Between Surveillance Imaging and Survival Outcomes in Small Bowel Neuroendocrine Tumors, Akie Watanabe, MD, University of British Columbia, Abstract ID: 167

C-34 - An Initial Experience in Establishing a Theranostic Precision Medicine PRRT Targeted Radiotherapy Program for the Treatment of  GEP-NETs with Lu-177 Dotatate (Lutathera) in a Major Academic University Hospital, Patrick Wojtylak, BS, University Hospitals of Cleveland, Cleveland Medical Center, Nuclear Medicine/Radiology, Abstract ID: 173

C-35 - Real-World Analysis Of Safety And Tolerance Of Repeat Peptide Receptor Radionuclide Therapy, Justin Chau, MD, University of Iowa Hospitals and Clinics, Hematology, Oncology, and Bone Marrow Transplantation, Abstract ID: 192

C-36 - Oral Abstract Presenter - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET, Ebrahim Delpassand, MD, RadioMedix, Abstract ID: 193

C-37 - Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine Tumors (NET), Heying Duan, MD, Stanford University, Radiology, Division of Nuclear Medicine and Molecular Imaging, Abstract ID: 194

C-38 - Hepatotoxicity in Previously Treated Y-90 Metastatic Neuroendocrine Cancer Patients after PRRT: Single Institution Experience, Yee Lan Wong, PA-C, Medical College of Wisconsin, Abstract ID: 197

C-39 - Hematotoxicity of peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience, Heying Duan, MD, Stanford University, Radiology, Division of Nuclear Medicine and Molecular Imaging, Abstract ID: 199

C-40 - Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – a single institution experience, Heying Duan, MD, Stanford University, Radiology, Division of Nuclear Medicine and Molecular Imaging, Abstract ID: 201

[return to category list

Clinical - Surgical and Applied Pathology

C-41 - Preoperative Risk Stratification Of Lymph Node Metastasis For Non-Functional Pancreatic Neuroendocrine Neoplasm: An International Dual-Institutional Study, Yosuke Kasai, MD, PhD, Kyoto University, Surgery, Abstract ID: 12

C-42 - Response Rates in Metastatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy and Implications for Future Treatment Strategies, Tanaz  Vaghaiwalla, MD, University of Chicago Medical Center, Surgery, Abstract ID: 13

C-43 - Ultrasound-guided percutaneous ethanol ablation for loco-regional recurrence of Medullary Thyroid Cancer, Thomas Szabo, MD, Yamashita, Mayo Clinic, Abstract ID: 46

C-44 - ISL-1 Expression Is a Prognostic Marker In Patients With Well-Differentiated Pancreatic Neuroendocrine Tumors, Hussein Assi, MD, Boston University/Boston Medical Center, Hematology/Oncology, Abstract ID: 62

C-45 - It’s Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors, Catherine Tran, MD, University of Iowa, Department of Surgery, Abstract ID: 103

C-46 - Symptom and Quality Of Life Impairments in Cushing’s Disease Before and After Endoscopic Transsphenoidal Surgery, Tony Huang, BS, St. Michael's Hospital, Division of Neurosurgery, Abstract ID: 107

C-47 - Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems, Heather Wachtel, MD, University of Pennsylvania, Surgery, Abstract ID: 127

C-48 - Metabolic Changes in Pheochromocytoma And Paraganglioma: Correlation Between Plasma Hormone Levels, Weight And Diabetes, Lauren Krumeich, MD, University of Pennsylvania, Surgery, Abstract ID: 128

C-49 - Pattern of Disease Recurrence and Treatment after Surgery for Nonfunctioning Well-Differentiated Pancreatic Neuroendocrine Tumors (NF-PanNET), Valentina Andreasi, MD, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center, Abstract ID: 150

C-50 - Socioeconomic Disparities in Midgut Neuroendocrine Tumors (MNETs): An NCDB Analysis, Timothy Diperi, MD, Cedars Sinai Medical Center, Department of Surgery, Abstract ID: 169

C-51 - A Novel Stratification Of Mesenteric Mass Involvement as a Predictor of Challenging Mesenteric Lymph Node Dissection by Minimally Invasive Approach for Ileal Neuroendocrine Tumors, Yosuke Kasai, MD, PhD, Kyoto University, Surgery, Abstract ID: 172

C-52 - Upfront Interventional Treatments Prior to Liver-Progression for Small Bowel Neuroendocrine Liver Metastasis, Yosuke Kasai, MD, PhD, Kyoto University, Surgery, Abstract ID: 174

C-53 - Well-Differentiated Rectal Neuroendocrine Tumors: Analysis of Histology, Including INSM1 Expression, and Biologic Behavior, Involving a Large Cohort of 94 Cases, Ryan Sappenfield, MD, Washington University in St. Louis, Pathology and Immunology, Abstract ID: 181

C-54 - Survival After Resection of Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasm: Association of Nodal Involvement and Survival, Lucas Thornblade, MD, MPH, City of Hope National Medical Center, Department of Surgery, Abstract ID: 190

C-55 - The Proliferative Indices of the Primary Ileal Well-Differentiated Neuroendocrine Tumors, Corresponding Lymph Nodes/Mesenteric Deposits, and Distant Metastatic Sites Show Poor Correlation, Jane Lee, MD, Washington University, Pathology and Immunology, Abstract ID: 204

[return to category list

Population Science 

P-1 - Oral Abstract Presenter - Cross-Sectional Study Assessing the Feasibility of Using NET VITALS communication Tool Among Patients With Neuroendocrine Tumors, Daneng Li, MD, City of Hope, Abstract ID: 37

P-2 - Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States, Shrunjal Shah, MD, Roswell Park Comprehensive Cancer Center, Department of Internal Medicine/ Hematology & Medical Oncology, Abstract ID: 73

P-3 - Oral Abstract Presenter - Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity Matched Comparative Population-Based Analysis, Sean Bennett, MD, University of Toronto, Surgery, Abstract ID: 76

P-4 - Mapping the Patient Journey to Neuroendocrine Tumor (NET) Diagnosis Using Real-World Data (RWD), David Ray, PharmD, MBA, MPH, Ipsen, Abstract ID: 98

P-5 - Costs Associated with Misdiagnoses of Neuroendocrine Tumors (NET), Alexandria Phan,MD, UT Health North Campus, Abstract ID: 99

P-6 - Real World Analysis of Misdiagnosis Among Patients with Neuroendocrine Tumors (NET), Callisia Clarke, MD, Medical College of Wisconsin, Abstract ID: 100

P-7 - Oral Abstract Presenter - Retrospective Analysis of DIPNECH and carcinoid Tumorlets Progressing to Invasive Pulmonary Carcinoid Tumors, Thomas Yang Sun, MD, Stanford School of Medicine, Division of Oncology, Abstract ID: 140

P-8 - Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients with Neuroendocrine Tumors, Eric Liu, MD, The Neuroendocrine Institute at Rocky Mountain Cancer Centers, Abstract ID: 175

P-9 - Risk of cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors (NETs): A Population-Based Analysis, Julie Hallet, MD, University of Toronto, Surgery, Abstract ID: 180

P-10 - A Neuroendocrine Tumor (NET) Patient Survey of Experiences with Telemedicine during the COVID-19 Pandemic, Yvette Mattison, PhD, New Orleans Louisiana Neuroendocrine Tumor Specialists, Abstract ID: 183

P-11 - Intensive Personalized Program for Living with NENs as a Chronic Disease, Michael Rosenberg, BS, MENETS - Middle East Neuroendocrine Tumor Society, Abstract ID: 186

[return to category list

Trials in Progress 

T-1 - Circulating Tumor DNA (Ct DNA) as a Biomarker in High-Grade Gastroenteropancreatic Neuroendocrine Tumor, Sarbajit Mukherjee, MD, Roswell Park Comprehensive Cancer Center, Department of Medicine, Abstract ID: 116

T-2 - A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Aman Chauhan, MD, University of Kentucky, Internal Medicine/Medical Oncology, Abstract ID: 155

T-3 - Cabozantinib in High Grade Neuroendocrine Neoplasms, Nikolaos Trikalinos, MD, Washington University in St Louis, Internal Medicine / Medical Oncology, Abstract ID: 161

T-4 - Randomized, Parallel Arm, Phase II Study of Telotristat  in Combination With Lutetium Lu 177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors (NETs), Aman Chauhan, MD, University of Kentucky, Internal Medicine/Medical Oncology, Abstract ID: 188

[return to category list

Other Science 

O-1 - Neuroendocrine Wellness Clinic- Holistic Care Delivery to Patients With Metastatic Neuroendocrine Tumors, Angela  Laffan, NP, University of California San Francisco, GI Medical Oncology/Survivorship, Abstract ID: 79

O-2 - Development and Validation of the Disease-Specific QOL-CD Quality of Life Questionnaire for Patients with Cushing’s Disease, Tony Huang, BS, St. Michael's Hospital, Division of Neurosurgery, 30 Bond Street, M5B 1W8, Toronto, CA, Abstract ID: 108

O-3 - Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – USA and Canada vs Global Diagnosis of NETs, Teodora Kolarova, MD, International Neuroendocrine Cancer Alliance, Abstract ID: 126

O-4 - Identifying Care Processes Promoting Person-Centred Care for Patients Diagnosed With Neuroendocrine Tumours (NETs), Julie Hallet, MD, University of Toronto, Surgery, Abstract ID: 129

O-5 - Supporting Accurate Patient Information for an Uncommon Malignancy: Evaluation of the Quality of Information on Neuroendocrine Tumors (NETs) on the Internet, Safa Sohail, BS, Sunnybrook Research Institute, Abstract ID: 131

O-6 - Diagnostic Effectiveness of Chromogranin A and Multigene Liquid Biopsy (NETest) in Neuroendocrine Neoplasia: An assessment of Monoanalyte and Multianalyte Biomarker Efficacy, Anna Malczewska, MD, PhD, Medical University of Silesia, Department of Endocrinology and Neuroendocrine Tumors, ENETS Center of Excellence, Abstract ID: 153

O-7 - Stereotactic Ablative Radiotherapy for the Management of Neuroendocrine Liver Metastases, John Hudson, MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Radiation Oncology, Abstract ID: 166

O-8 - Role of Chromogranin A-derived Fragments as Biomarkers for Pancreatic Neuroendocrine Tumors (PanNET), Valentina Andreasi, MD, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Cente, Abstract ID: 168

O-9 - Patient Experience with Somatostatin Analog Treatments for Neuroendocrine Tumors: Insight from Qualitative Interviews, David Ray, PharmD, MBA, MPH Ipsen Biopharmaceuticals, Abstract ID: 171

O-10 - Neuroendocrine Carcinoma of the Rectum & Anus: Patient Characteristics and Treatment Modalities, Benjamin Ueberroth, MD, Mayo Clinic, Internal Medicine, Abstract ID: 191

O-11 - The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations And Persistence Rates, Simron Singh, MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Division of Medical Oncology, Abstract ID: 178

[return to category list